All of the powerhouses of pharmaceutical manufacturing companies have joined together to form TransCelerate BioPharma, as a way to bring new drugs to the market more quickly.
Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech - a member of the Roche Group, and Sanofi will work together across the global research and development community and share research and solutions that will ‘simplify and accelerate the delivery of exciting new medicines for patients," according to newly appointed interim CEO of TransCelerate, Garry Neil, MD, Partner at Apple Tree Partners and formerly Corporate VP, Science & Technology, Johnson & Johnson.
We aim to reduce bottlenecks in R&D and increase efficiency. This is all about accelerating transformative innovation. We have an obligation to stakeholders to find…new and transformative ways of doing things. We are really working collectively in a way we haven’t done before,” said Neil.
Each of the ten founding companies will combine financial and other resources, including personnel, with a total of five projects having already been selected for development.
“This new non-profit will foster pre-competitive collaboration to improve the drug development success rate,” said Carola Schropp, President of EBD Group.
